<DOC>
	<DOCNO>NCT02033551</DOCNO>
	<brief_summary>This extension study evaluate safety Veliparib monotherapy combination Carboplatin plus Paclitaxel modify Folinic Acid/Fluorouracil/Irinotecan ( FOLFIRI ) subject solid tumor .</brief_summary>
	<brief_title>A Study Evaluating Veliparib Single Agent Combination With Chemotherapy Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Must confirm solid malignancy metastatic , standard curative measure therapy may provide clinical benefit exist longer effective . For Veliparib monotherapy ( must tumor defect DNA repair mechanism ( BRCA mutation high grade ovarian cancer solid tumor combination therapy . If subject know brain metastasis must clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 21 day stable neurologic function evidence Central Nervous System ( CNS ) disease progression determine compare compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) scan perform screen prior scan perform least 4 week earlier provide subject asymptomatic , evidence cavitation hemorrhage , require corticosteroid ( must discontinue steroid least 3 month prior study drug administration ) . Subject must adequate bone marrow , renal hepatic function per local laboratory reference range . Subject clinically significant uncontrolled major medical condition ( ) include limited : Uncontrolled seizure disorder , include focal generalized seizure within last 12 month ; Uncontrolled nausea/vomiting/diarrhea ; Active uncontrolled infection ; Symptomatic congestive heart failure ; Unstable angina pectoris cardiac arrhythmia ; Psychiatric illness/social situation would limit compliance study requirement ; Any medical condition , opinion study investigator , place subject unacceptably high risk toxicity . Subjects hypersensitivity Carboplatin , Paclitaxel Cremophor exclude arm B . Subject receive follow anticancer therapy 21 day prior first dose study drug biologic agent antineoplastic intent within 30 day prior first dose study drug . Subject require parenteral nutrition , tube feed evidence partial bowel obstruction perforation within 28 day prior study drug . The subject another active malignancy within past 3 year except cancer situ Principal Investigator considers cure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>PARP Inhibitor</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Colon Cancer</keyword>
</DOC>